FDA approves Protein Sciences’ Flublok to prevent seasonal influenza

The US Food and Drug Administration has approved Protein Sciences Corporation's vaccine Flublok for the prevention of seasonal influenza in adults 18 to 49 years of age. Diamyd Medical holds about 8 percent of the shares in Protein Sciences Corporation.

Flublok is a recombinant protein-based seasonal influenza vaccine and the first influenza vaccine manufactured using recombinant technology that has received marketing approval by the FDA. Protein Sciences Corporation is planning to have a limited launch of the product in February 2013 with the full launch occurring in time for the 2013/14 influenza season.


Protein Sciences Corporation


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Characterizing spillover dynamics and global transmission patterns of avian influenza A viruses